glp 1 agonists and sglt2 inhibitors Complementary Yet Distinct Roles of GLP-1 Receptor in Cardiovascular Risk Reduction SGLT2 Inhibitors and GLP-1 Receptor

Description

Here are some key requirements from this guidance

I cant explain it

National Institute for Health and Care Excellence (NICE)

Researchers are responsible for ensuring proper handling, storage, preparation, compatibility review, and compliance with all applicable regulations

The emergence of tri-agonists, combining GLP-1R/GIPR and glucagon (GCG) receptor (GCGR) agonists (GLP-1R/GIPR/GCGR agonist), has also shown promising results by leading to more significant weight loss, a greater percentage of individuals attaining weight loss, further lowering lipid levels, improving T2DM management, and enhancing overall substrate metabolism compared to the use of GLP-1R agonists alone (Lyons & Beaudry 2023)